Scientific Breakthroughs of the Week — August 22, 2026
🧬 Life Sciences & Medicine Individualised mRNA cancer vaccine meets its phase 3 endpoints – Merck and Moderna reported that adding intismeran autogene, an individualised mRNA neoantigen therapy, to pembrolizumab lengthened recurrence-free survival after melanoma surgery. The INTerpath-001 trial randomised 1,137 patients with resected stage IIB to IV melanoma 2 to 1, and met its […]
